跳至主要内容
临床试验/ITMCTR2000003509
ITMCTR2000003509招募中4 期

A randomized controlled trial of Naoxintong Capsule to reduce major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS)

The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • (1) Aged 30-75 years;
  • (2) Meet the diagnostic criteria of ACS;
  • (3) Subjects voluntarily participate in this study and sign written informed consent.

排除标准

  • (1) Patients with severe arrhythmia, such as type II ATRIoventricular block and pathological sinoatrial node syndrome; Severe hypotension, hypertension emergency, severe heart failure (grade III or above cardiac function, not effectively controlled), acute cardiac tamponade, acute pulmonary edema, etc.
  • (2) Patients with hemorrhagic cerebrovascular accident and gastrointestinal bleeding;
  • (3) Hemophilia, severe thrombocytopenia, abnormal coagulation function;
  • (4) Complications of severe diabetes, such as diabetic ketoacidosis;
  • (5) patients with severe liver and kidney function impairment (3 times of the normal upper limit of serum alanine aminotransferase > and/or serum creatinine level >= 265umol/L);
  • (6) Patients with malignant tumors and mental diseases;
  • (7) Patients who need coronary bypass graft (heart bypass);
  • (8) Allergic to the known ingredients of the test drugs or allergic constitution;
  • (9) Severe hypotension;
  • (10) Severe respiratory diseases such as chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism.
  • (11) women who are breast-feeding or pregnant, or women of childbearing age who plan to become pregnant within 6 months after screening examination, or who are positive in urine pregnancy test; Or male patients with fertility or sperm donation plans;
  • (12) Suspected or proven history of alcohol or drug abuse;
  • (13) Screening patients who had participated in other drug clinical trials within 3 months before the examination;
  • (14) Other patients who were not considered appropriate to participate in this study by the researchers.

研究者

发起方
The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

相似试验